After successfully establishing and characterizing PRCC-TFE3 fusion tRCC organoids, we focused on developing a three-dimensional (3D) cell-based assay that was suitable for HTS. The gene discussed is TFE3; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.